UPC (Universe Pharmaceuticals) Risk Assessment


UPC Universe Pharmaceuticals Inc UPC
62 GF Score
Price $6.21
GF Value $5.20
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Universe Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Universe Pharmaceuticals is: High Risk: High uncertainty with risk-return tradeoff.

Universe Pharmaceuticals  (NAS:UPC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Universe Pharmaceuticals Risk Assessment Related Terms

UPC vs CPMD, SHPH, NPHC: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universe Pharmaceuticals Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Universe Pharmaceuticals's Risk Assessment falls into.


UPC
62GF Score
Universe Pharmaceuticals Inc UPC
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Universe Pharmaceuticals (UPC) Overvalued in 2026?

Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be overvalued. The current stock price of $6.21 is trading 19.4% above its estimated GF Value™ of $5.20. GuruFocus considers Universe Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for UPC:

  • Risk Assessment:
  • GF Value™: $5.20 vs. price of $6.21 (19.4% above fair value)
  • GF Score™: 62/100 with 9 warning signs

No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Universe Pharmaceuticals Business Description

Address 265 Jingjiu Avenue, Jinggangshan Economic & Technological Development Zone, Jiangxi, Ji’an, CHN, 343100
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
62GF Score

Get the complete analysis for UPC

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.21
Price
$5.20
GF Value